BioSpace News Archive

The National Kidney Registry (NKR) and Viracor Eurofins announced a partnership today to deliver testing for Coronavirus SARS-CoV-2 (the virus that causes COVID-19 disease) to NKR’s vast network of Member Centers

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the first participant has been dosed in the Phase 1 study of the Company’s mRNA vaccine (mRNA-1273) against the novel coronavirus (SARS-CoV-2).

modmed® Telehealth; to be available at no additional charge to EMA® customers during COVID-19 crisis

Blue Cross and Blue Shield of Minnesota (Blue Cross), the state’s leading health insurer, has announced immediate no-cost coverage updates as part of its ongoing effort to help prevent the spread and impact of the coronavirus (COVID-19).

Harvest Health & Recreation Inc. (CSE: HARV, OTCQX: HRVSF) (“Harvest”), a vertically integrated cannabis company with one of the largest and deepest footprints in the U.S., today announced that it completed the merger with Interurban Capital Group, Inc. on March 13, 2020, that was previously announced by Harvest on March 11, 2020.

Cerner Corporation, a global health care technology company, announced the Hon. Patrick Murphy as new chairman of the Cerner Government Advisory Board.

LogicBio Therapeutics, Inc., a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, reported financial results and provided a corporate update for the year ended December 31, 2019.

AVEO Oncology reported financial results for the full year ended December 31, 2019 and provided a business update.

RTI Surgical Holdings, Inc., a global surgical implant company, announced it will file a Form 12b-25 Notification of Late Filing with the Securities and Exchange Commission to provide a 15 calendar day extension within which to file its Form 10-K for the fiscal year ended December 31, 2019.

- PROTECT Study Randomization to be Paused Temporarily in Response to the Ongoing Public Health Crisis - Company Reaffirms it is on Schedule to Complete PRV-031 (teplizumab) Rolling BLA Submission for Prevention or Delay of T1D in At-risk Individuals